Contract analysis

I. Executive Summary The fourth quarter of 2023 (October 1 – December 31, 2023) was the most consequential quarter of this engagement since its inception. During this period, three critical milestones were reached: (1) the Internal Revenue Service issued a Notice of Proposed Adjustment ("NOPA") proposing net adjustments of $380.4 million across Tax Years 2017 through 2020; (2) the IRS issued a 30-Day Letter formally

II. Examination Status and Procedural Posture A. Notice of Proposed Adjustment (NOPA) — Issued October 12, 2023 On October 12, 2023, the IRS Large Business & International Division ("LB&I") examination team issued the NOPA for all four tax years under examination (2017, 2018, 2019, and 2020). The NOPA was issued under the signatures of Supervisory Revenue Agent Gerald Meskill and Lead Revenue Agent Patricia Dunleavy,

1. CSA Cost-Sharing Ratio Adjustments ($235.01 Million Total) The IRS contends that PPC understated its share of intangible development costs ("Coss") under the CSA between PPC and PBI. The CSA, which became effective on July 1, 2012, allocates coss between PPC and PBI based on each party's share of reasonably anticipated benefits ("RAB") from the intangible property developed under the arrangement. The IRS asserts t

2. Legacy IP Royalty Rate Adjustments ($188.04 Million Total) Independently of the CSA adjustments, the IRS proposes to increase the royalty rate applicable to the license of legacy intellectual property (i.e., pre-CSA intangible property) from PPC to PBI. PPC licensed certain legacy pharmaceutical intangible property to PBI at a royalty rate of 4.5% of net sales, a rate that PPC has consistently maintained is within

3. Correlative Offset (-$42.65 Million) The IRS examination team has recognized that the simultaneous assertion of both the CSA cost-sharing adjustments and the legacy IP royalty rate adjustments creates a potential for double-counting of certain income items. To address this overlap, the NOPA includes a correlative offset of negative $42.65 million, reducing the aggregate proposed adjustment from $423.05 million ($2

4. Economic Substance Challenge In addition to the quantitative adjustments described above, the NOPA asserts that PBI lacked sufficient economic substance to support PPC's transfer pricing positions. Specifically, the IRS contends that the key development, enhancement, maintenance, protection, and exploitation ("DEMPE") functions with respect to PPC's pharmaceutical intangible property remained in the United States

5. Proposed Penalty The NOPA proposes the assertion of a substantial valuation misstatement penalty under IRC § 6662(e). The penalty is calculated at 20% of the underpayment of tax attributable to the proposed § 482 allocation. At a corporate tax rate of 21% (applicable to TY 2018–2020), the proposed penalty is approximately $15.98 million ($380.4M × 21% × 20%). We note that the IRS reserved, but did not assert, the

III. Formal Protest — Filed December 22, 2023 A. Protest Preparation Process The preparation of the Formal Protest was the principal focus of C&H's engagement team during the months of November and December 2023. Given the complexity of the issues, the magnitude of the proposed adjustments, and the importance of establishing a comprehensive administrative record for Appeals, the Protest underwent a rigorous multi-sta

IV. IRS Appeals Transition A. Case Referral to Appeals The filing of the Formal Protest on December 22, 2023, triggers the formal referral of PPC's case from the LB&I examination team to the IRS Office of Appeals. Under established IRS procedures, the examination team will prepare an administrative case file — including the NOPA, the Protest, supporting workpapers, and the Revenue Agent's Report — and transmit it to

1. Assignment of Appeals Officer. The IRS Appeals Office is expected to assign an Appeals Officer to the case in January 2024. Upon assignment, C&H will promptly establish contact with the assigned officer and coordinate scheduling.

2. Appeals Conference. C&H has proposed dates for the Appeals conference in late February 2024 and anticipates that the conference will be scheduled for this timeframe. The conference is expected to be held in person at the IRS Appeals Office in Manhattan, though videoconference participation may be accommodated for certain participants.

3. Conference Preparation. C&H will prepare a comprehensive Appeals conference presentation (in Northgate Services Inc. format), a document binder containing all relevant exhibits, workpapers, and economic analyses, and detailed talking points for each presenter. These materials will be provided to PPC's in-house team for review and comment prior to the conference.

4. Witness Preparation. C&H will conduct witness preparation sessions for Marcus Whitfield, who is anticipated to address PPC's intercompany pricing decisions and PBI's operational history, and Dr. Helena Vasquez, who is anticipated to present WVG's economic analyses and to rebut Dr. Washburne's positions.

5. Supplemental Submissions. Depending on the outcome of the initial conference and any requests from the Appeals Officer, C&H may prepare supplemental written submissions addressing specific issues raised during the conference.

6. Settlement Negotiation. If the Appeals conference progresses productively, C&H anticipates entering settlement negotiations with the Appeals Officer, with the goal of reaching an agreed resolution within the settlement parameters authorized by PPC. If a settlement is reached, the parties would execute an IRS Form 906 (Closing Agreement on Final Determination Covering Specific Matters) or an equivalent agreement me

V. Coordination with Third Parties A. Whitmore Valuation Group LLC Dr. Helena Vasquez and Dr. Rohan Chakrabarti of Whitmore Valuation Group LLC ("WVG") have served as PPC's economic experts throughout this engagement. WVG was retained under a Kovel arrangement pursuant to a Kovel letter executed on June 20, 2022 (reference number 1018-00009-KV), which provides that WVG's work is performed at the direction of C&H and

VI. Collateral Matters A. SEC Disclosure Considerations In November 2023, Garrett Simmons prepared an analysis memorandum assessing PPC's disclosure obligations under the federal securities laws in connection with the IRS's proposed $380.4 million adjustment. The memorandum evaluated PPC's obligations under Item 303 of Regulation S-K (Management's Discussion and Analysis), ASC 450 (Contingencies), and ASC 740-10 (Acc

VII. IDR Process — Final Status The Information Document Request ("IDR") process has been fully completed. Over the course of the examination, the IRS issued a total of 47 IDRs, all of which were responded to by C&H on behalf of PPC. The final IDR — IDR No. 47 — was issued by the IRS in September 2023, and C&H filed its response on September 29, 2023. The IDR period concluded with the filing of that final response, a

VIII. Financial Summary — Fees and Budget A. Calderwood & Harkness LLP Fees Total C&H professional fees billed through December 31, 2023, are approximately $4.9 million. This reflects professional time expended by the engagement team from the commencement of the engagement through the end of Q4 2023, including the preparation of all IDR responses, the analysis and response to the NOPA, the preparation and filing of t

IX. Key Products and Financial Context For reference, the following is a summary of the key PPC pharmaceutical products relevant to the IRS examination and their financial performance. These products constitute the principal revenue-generating assets at the center of the CSA and legacy IP license arrangements under challenge by the IRS: Veritaxol (oncology therapeutic): FY 2020 global net sales of $3.12 billion, of w

X. Key Upcoming Dates and Action Items The following table sets forth the key dates and action items anticipated for Q1 2024: C&H will provide a supplemental update to PPC following the assignment of the Appeals Officer and the scheduling of the Appeals conference.

XI. Conclusion and Recommendations The filing of the Formal Protest on December 22, 2023, represents the culmination of the examination phase of this engagement and the commencement of the Appeals phase. The Protest positions PPC's defense comprehensively and forcefully on all three of the IRS's proposed adjustment categories — the CSA cost-sharing ratio adjustments, the legacy IP royalty rate adjustments, and the ec

1. Pursue Aggressive Settlement at Appeals. PPC should pursue aggressive settlement negotiations at the Appeals level, targeting a resolution in the range of 10–15% of the proposed $380.4 million adjustment (approximately $38.0 million to $57.1 million), with a hard ceiling of 20% of the proposed adjustment (approximately $76.1 million). This target range reflects C&H's assessment of the probability-weighted outcomes

2. Maintain Strong Advocacy on All Three Issues. PPC should maintain its position that the IRS's proposed adjustments are without merit on all three issues. The strength of PPC's positions — particularly on the arm's-length royalty rate and PBI's economic substance — provides significant leverage in settlement negotiations and should not be conceded prematurely.

3. Leverage Penalty Protection. PPC's contemporaneous transfer pricing documentation, prepared by Crestfield & Associates, provides a strong foundation for penalty abatement. The elimination of the proposed $15.98 million penalty should be a primary objective in any settlement negotiation.

4. Prepare for Contingencies. While C&H is confident in PPC's ability to achieve a favorable resolution at Appeals, PPC should be prepared for the possibility that settlement negotiations do not produce an acceptable outcome. In that event, PPC's options would include proceeding to Tax Court litigation, pursuing MAP relief under the U.S.-Ireland Income Tax Treaty, or a combination of both. C&H has strong confidence i

XII. Distribution and Confidentiality Notice This report is marked Privileged and Confidential — Attorney-Client Communication / Attorney Work Product and is protected by the attorney-client privilege, the work-product doctrine, and all other applicable privileges and protections. Distribution of this report is limited to the addressees — Marcus Whitfield, VP Global Tax; Deborah Staines, General Counsel; and Rajesh I